8 results
treatment outcome in OCD. Objective: The objective for this study is fourfold. First we will determine whether DCS addition to behavioural exposure therapy may enhance fear extinction and improve symptoms in OCD. Our hypothesis is that improvement…
The objective for this study is threefold. First we will determine whether DCS addition to behavioural exposure therapy may enhance fear extinction and improve symptoms in BDD. Our hypothesis is that improvement will occur and at a faster rate than…
The aim of this pilot-study is to establish the potential efficacy of acute doses of 50 mgs D-cycloserine (DCS), a partial NMDA agonist, in accelerating and/or augmenting the effect of exposure and response prevention (ERP) in the treatment of…
The present study is aimed at testing the effects of D-cycloserine in addition to exposure treatment sessions in PTSD patients, in a randomized double blind placebo controlled study.
The first aim of the study is to investigate whether DCS addition to exposure therapy enhances symptom reduction in PD+AGO. The second objective of the study is to establish the optimal timing of administration of DCS (30 minutes before or directly…
(1) Establishing normal values (cut-offs) for bipolar and unipolar voltage mapping during sinus rhythm and pacing. (2) Establish normal values for conduction velocity during sinus rhythm of the 4 chambers. (3) Establish normal values for activation…
Primary clinical investigation objectives[Safety]The primary safety objective of the clinical investigation is to provide data that demonstrates safety of the device, defined as < 8.3% serious adverse device effects, up to 6 weeks following…
The primary objective is to test the role of NMDA receptor-dependent learning in an experimental model of conditioned nocebo effects on self-reported pain (sub-study 1) and itch (sub-study 2). Secondary objectives are to examine the role of NMDA…